The performance of companies tied to the drug's past presents a complex investment scenario . While the initial surge generated substantial gains, generic copies have significantly eroded revenue. Investing in connected pharmaceutical firms now requires a careful assessment of intellectual property safeguards, evolving healthcare changes, and the p